CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Planned sale Sinha Vikas sold 2,683 shares at an average $3.66 ($9,828)
- 4 Planned sale Chief Accounting Officer sold 697 shares at an average $3.67 ($2,556)
- 4 Planned sale Chief Executive Officer sold 8,408 shares at $3.71 ($31,183)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 5,122 shares at $6.63 ($33,935)
- 4 Grant or award Sinha Vikas acquired 157,500 shares (grant or award)
- 4 Grant or award General Counsel acquired 87,500 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 81,006 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 61,250 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 332,500 shares (grant or award)
- 4 Open-market sale Sinha Vikas sold 6,537 shares at an average $5.09 ($33,287)
- 4 Open-market sale General Counsel sold 2,573 shares at an average $5.09 ($13,101)
- 4 Open-market sale Chief Accounting Officer sold 1,895 shares at an average $5.09 ($9,645)
- 4 Open-market sale Chief Executive Officer sold 34,435 shares at $5.08 ($174,851)
- 4 Open-market sale Chief Executive Officer sold 4,515 shares at $7.27 ($32,810)
Page 9 of 19 · 363 filings